Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Donggoo Bae"'
Autor:
Hae-Mi Kim, Kyoung-Jin Kim, Kwanghyun Lee, Myeong Jin Yoon, Jenny Choih, Tae-Joon Hong, Eun Ji Cho, Hak-Jun Jung, Jayoung Kim, Ji Soo Park, Hye Young Na, Yong-Seok Heo, Chae Gyu Park, Heungrok Park, Sungho Han, Donggoo Bae
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-14 (2024)
Abstract Background Several PD-1 antibodies approved as anti-cancer therapies work by blocking the interaction of PD-1 with its ligand PD-L1, thus restoring anti-cancer T cell activities. These PD-1 antibodies lack inter-species cross-reactivity, nec
Externí odkaz:
https://doaj.org/article/606d5df8b1b947599105dd20763d2262
Autor:
Eunju Choi, Jenny Choih, Hak-Jun Jung, Kwanghyun Lee, Sungho Han, Donggoo Bae, Heungrok Park, June Myoung Kim, Hyun Soo Shin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/14c1fcd7d4694f3b94c0d3d5a10a5029
Autor:
Seung-Beom Hong, Hyun-Soo Cho, Donggoo Bae, Youngsoo Sohn, Kyungyong Kim, Uijin Kim, Myung Kyung Choi, Jeong Seok Cha, Ju Yeon Kim, Miyoung Kim, Youngki Yoo, Mirim Hong
Figure S1-S6, Table S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1da06b32ca87a590a92172bea30ca53
https://doi.org/10.1158/1535-7163.22522825
https://doi.org/10.1158/1535-7163.22522825
Autor:
Haemi Kim, Kyoung-Jin Kim, Myeong Jin Yoon, Jenny Choih, Eun Ji Cho, Hak-Jun Jung, Kwanghyun Lee, Jayoung Kim, Chae Gyu Park, Sungho Han, Donggoo Bae, Heungrok Park
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f68be94ae768b2130422151cf1e7980d
https://doi.org/10.1136/jitc-2022-sitc2022.0488
https://doi.org/10.1136/jitc-2022-sitc2022.0488
Autor:
Hae-Mi Kim, Kyoung-Jin Kim, Eun Ji Cho, Jayoung Kim, Myeong Jin Yoon, Ji Soo Park, Hye Young Na, Chae Gyu Park, Donggoo Bae, Heungrok Park
Publikováno v:
Journal of Clinical Oncology. 40:e14509-e14509
e14509 Background: Several PD-1 antibodies have been recently approved as anti-cancer therapies which work by blocking the interaction of PD-1 with its ligand PD-L1, thus restoring anti-cancer T cell activities. However, cross-reactive anti-PD-1 anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86013ff4cd09c47f04c8234b74ba691b
https://doi.org/10.1200/jco.2022.40.16_suppl.e14509
https://doi.org/10.1200/jco.2022.40.16_suppl.e14509
Autor:
Ju Yeon Kim, Jeong Seok Cha, Hyun Soo Cho, Myung Kyung Choi, Seung Beom Hong, Donggoo Bae, Uijin Kim, Kyungyong Kim, Mirim Hong, Miyoung Kim, Youngki Yoo, Youngsoo Sohn
Publikováno v:
Molecular cancer therapeutics. 20(6)
ErbB3, a member of the ErbB receptor family, is a potent mediator in the development and progression of cancer, and its activation plays pivotal roles in acquired resistance against anti-EGFR therapies and other standard-of-care therapies. Upon ligan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0faf781ffb035e86567a239a3e42526
https://pubmed.ncbi.nlm.nih.gov/33782100
https://pubmed.ncbi.nlm.nih.gov/33782100
Autor:
Seung-Beom Hong, Donggoo Bae, Jung Won Kim, Ju Yeon Kim, Bongseok Shin, Jeongin Cho, Tae Eun Kim, Mirim Hong
Publikováno v:
Cancer Research. 80:3042-3042
ErbB3, a heterodimeric partner of EGFR or ErbB2, plays important roles in the survival and growth of cancer cells through activation of PI3K/AKT pathway. ErbB3 can be activated by NRG1 expressed either by cancer cells or adjacent mesenchymal cells, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5b009ec657552dc73ec15779fc6b83a
https://doi.org/10.1158/1538-7445.am2020-3042
https://doi.org/10.1158/1538-7445.am2020-3042
Autor:
Hira Lal Goel, Shaolei Lu, Arthur M. Mercurio, Donggoo Bae, Bryan M. Pursell, Lindsey M. Gouvin
Publikováno v:
Development. 138:2969-2976
Although the neuropilins were characterized as semaphorin receptors that regulate axon guidance, they also function as vascular endothelial growth factor (VEGF) receptors and contribute to the development of other tissues. Here, we assessed the role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9a4729d3437527be79d8cab59876908
https://doi.org/10.1242/dev.051318
https://doi.org/10.1242/dev.051318
Autor:
Miyoung Kim, Youngmi Hur, Mirim Hong, Youngsoo Sohn, Kum-Joo Shin, Kyungyong Kim, Seung-Beom Hong, Donggoo Bae
Publikováno v:
Cancer Research. 78:836-836
ErbB3 is noted as one of major causes of acquired cetuximab resistance in colorectal and head and neck cancers. ErbB3 causes activation of alternative signaling pathways that bypass the original target and sustained PI3K/AKT activation, and these are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bbc157dbd37df92be88f31c5ec83a06
https://doi.org/10.1158/1538-7445.am2018-836
https://doi.org/10.1158/1538-7445.am2018-836
Autor:
Vishva Mitra Sharma, Donggoo Bae, Paul Mak, Cherie A. Taglienti, Arthur M. Mercurio, Irwin Leav, Bryan M. Pursell, Xiaofang Yang, Lindsey M. Gouvin
Publikováno v:
Cancer Cell. 17:319-332
High Gleason grade prostate carcinomas are aggressive, poorly differentiated tumors that exhibit diminished estrogen receptor beta (ERbeta) expression. We report that a key function of ERbeta and its specific ligand 5alpha-androstane-3beta,17beta-dio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d8ecdb8b4e265ea98186969d6a89e14
https://doi.org/10.1016/j.ccr.2010.02.030
https://doi.org/10.1016/j.ccr.2010.02.030